Related Experiment Videos
Ifosfamide-induced renal tubular defect
M J Torres Valdivieso1, J López Pérez, C Melero
1Department of Pediatric Hematology-Oncology, Social Security Hospital 12 de Octubre, Madrid, Spain.
Medical and Pediatric Oncology
|January 1, 1994
Summary
Ifosfamide treatment in children with cancer can cause kidney damage. Dividing the drug dosage may reduce this risk, but further research is needed to confirm its safety.
Area of Science:
- Pediatric Oncology
- Nephrology
- Clinical Pharmacology
Background:
- Ifosfamide is a chemotherapeutic agent used for malignant mesenchymal tumors in children.
- High-dose ifosfamide regimens can lead to significant toxicities, including renal dysfunction.
- Proximal tubular defects represent a specific type of kidney injury associated with ifosfamide.
Observation:
- Two pediatric cases of proximal tubular defects following ifosfamide administration are presented.
- The standard dosage was 6 g/m2/course over 2 days.
- These defects manifested as a consequence of the chemotherapy treatment.
Findings:
- The observed adverse effect was proximal tubular dysfunction.
- Dividing the ifosfamide dosage appeared to mitigate this specific toxicity.
- The long-term safety and efficacy of divided dosing regimens remain undetermined.
Implications:
- Consideration of divided ifosfamide dosing may reduce renal toxicity in pediatric cancer patients.
- Further clinical studies are warranted to validate the safety and effectiveness of modified dosing strategies.
- This highlights the importance of monitoring renal function during ifosfamide therapy in children.